<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cefotaxime Dosage Information</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            padding: 20px;
            background-color: #f9f9f9;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 20px;
            background-color: #fff;
            border-radius: 10px;
            box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1);
        }

        h1 {
            color: #fcf2f2;
            font-size: 28px;
            font-weight: bold;
            padding: 10px;
            border: 2px solid #afaaaa;
            border-radius: 10px;
            background-color: #2c8ed0;
            text-align: center; /* Center the text */
        }

        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 16px;
            text-align: center;
        }

        th, td {
            padding: 12px;
            border-bottom: 1px solid #ddd;
        }

        th {
            background-color: #f2f2f2;
        }

        .highlight {
            background-color: #c3e6cb;
        }

        .dose-range {
            color: red;
            font-weight: bold;
        }

        .section-title {
            margin-top: 20px;
            font-size: 18px;
            font-weight: bold;
        }

        .section-header {
        color: #808080; /* สีเทา */
        font-weight: bold;
        font-size: 20px; /* ขนาดตัวอักษร */
        padding: 10px;
        text-align: left; /* ชิดซ้าย */
        border-radius: 5px; /* เพิ่มขอบมน */
        margin-bottom: 10px; /* เพิ่มช่องว่างด้านล่าง */
    }

        .highlight-dose {
            color: #ff5733;
            font-size: 24px;
            font-weight: bold;
            background-color: #fbe9e7;
            padding: 5px 10px;
            border-radius: 5px;
        }

        .button-group {
            display: flex;
            justify-content: center;
            gap: 10px;
            margin-top: 20px;
        }

        .back-button, .back-button-secondary {
            padding: 10px 20px;
            font-size: 16px;
            cursor: pointer;
            text-align: center;
            text-decoration: none;
            outline: none;
            color: #fff;
            border: none;
            border-radius: 10px;
            box-shadow: 0 5px #999;
        }

        .back-button {
            background-color: #f44336;
        }

        .back-button:hover {
            background-color: #d32f2f;
        }

        .back-button-secondary {
            background-color: #008CBA;
        }

        .back-button-secondary:hover {
            background-color: #007B9A;
        }

        footer {
            text-align: center;
            color: #00000035;
            font-size: 14px;
            padding: 10px;
            width: 100%;
        }

        /* Mobile-Specific Adjustments */
        @media (max-width: 600px) {
            body {
                padding: 10px;
            }

            h1 {
                font-size: 20px; /* Reduce font size for mobile */
                padding: 5px; /* Reduce padding */
            }

            .highlight-dose {
                font-size: 20px; /* Adjust font size */
            }

            .section-title {
                font-size: 14px;
            }

            .table-wrapper {
                overflow-x: auto; /* Allow horizontal scrolling */
                margin-bottom: 15px;
            }

            table {
                font-size: 14px; /* Reduce font size */
            }

            th, td {
                padding: 8px; /* Reduce padding for smaller screens */
            }

        }
    </style>
</head>
<body>
        <h1>cefotaxime Dosage Information</h1>

        <!-- Display the calculated PMA and Postnatal Age -->
    <p><strong>PMA:</strong> {{ pma_weeks }} weeks and {{ pma_days }} days</p>
    <p><strong>Calc.:</strong> {{ calc }} weeks</p>
    <p><strong>Postnatal Age:</strong> {{ postnatal_days }} days</p>
    <p><strong>Birth Weight (BW):</strong> {{ bw }} kg</p>

    <!-- Display the calculated dosage for neonates -->
    <div class="section-title">Calculated Dosage for Neonates</div>
    <p><strong>Recommended Dose:</strong> <span class="highlight-dose">{{ calculated_dose }} mg</span></p>
   
        
<div class="section-header">DOSING/ADMINISTRATION</div>
        <div class="section-title">Dose</div>
        <p>
            <strong> Disseminated Gonococcal Infections and Gonococcal Scalp Abscesses:</strong> 25 mg/kg/dose IV or IM every 12 hours for 7 days, with a duration of 10 to 14 days if meningitis is documented 
        </p>

        <p><strong>Meningitis:</strong></p>
            <p><strong>0 to 7 days of age:</strong> 100 to 150 mg/kg/day IV divided every 8 to 12 hours. Consider smaller doses and longer intervals for very low-birth weight neonates (less than 2 kg).</p>
            <p><strong>8 days or older:</strong> 150 to 200 mg/kg/day IV divided every 6 to 8 hours. Consider smaller doses and longer intervals for very low-birth weight neonates (less than 2 kg).</p>

        <p><strong>Sepsis: </strong> The following recommendations were based on developmental pharmacokinetic-pharmacodynamic analysis (n=100) to achieve time above MIC (2 mg/L for postnatal age younger than 7 days and 4 mg/L for postnatal age 7 days or older) of 75%</p>
        
<table border="1" cellspacing="0" cellpadding="5">
    <thead>
        <tr>
            <th>Gestational Age (weeks)</th>
            <th>Postnatal Age (days)</th>
            <th>Regimen</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td>All weeks</td>
            <td>Younger than 7 days</td>
            <td>50 mg/kg/dose IV every 12 hours</td>
        </tr>
        <tr>
            <td>Less than 32 weeks</td>
            <td>7 days or older</td>
            <td>50 mg/kg/dose IV every 8 hours</td>
        </tr>
        <tr>
            <td>32 weeks or more</td>
            <td>7 days or older</td>
            <td>50 mg/kg/dose IV every 6 hours</td>
        </tr>
    </tbody>
    <tfoot>
        <tr>
            <td colspan="3" style="text-align: left;">Source: Leroux, 2016</td>
        </tr>
    </tfoot>
</table>

          <p><strong>Usual dose for bone and joint, genitourinary, intra-abdominal, lower respiratory tract, or skin and skin structure infection</strong></p>
          <p><strong>7 days or younger and any weight:</strong> 50 mg/kg/dose IV/IM every 12 hours.</p>
          <p><strong>8 days to 28 days and 2 kg or less:</strong> 50 mg/kg/dose IV/IM every 8 to 12 hours. </p>
          <p><strong>8 days to 28 days and more than 2 kg:</strong> 50 mg/kg/dose IV/IM every 8 hours.</p>


        <div class="section-title">Uses</div>
        <p><strong>Disseminated gonococcal infections and gonococcal scalp abscesses</strong>The recommended regimen is ceftriaxone or cefotaxime.</p>
          <p><strong>Infective endocarditis:</strong> The following recommendations are based on a consensus of experts. The full pediatric guidelines can be found here: https://doi.org/10.1161/CIR.0000000000000298</p>

<table>
      <thead>
            <tr>
                <th colspan="3">Organism Directed Therapy</th>
            </tr>
        </thead>
        <thead>
            <tr>
                <th>Organism</th>
                <th>First-Choice</th>
                <th>Alternative Choice</th>
            </tr>
        </thead>
        <thead>
            <tr>
                <th>Streptococci</th>
                <th colspan="2"></th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>
                    Highly susceptible to penicillin G (MBC 0.1 mcg/mL or less); includes most viridans streptococci, groups A, B, C, G nonenterococcal, group D streptococci (S bovis, S equinus)
                </td>
                <td>Penicillin G or CefTRIAXone</td>
                <td>Vancomycin or First-generation cephalosporin or CefTRIAXone</td>
            </tr>
            <tr>
                <td>
                    Relatively resistant to penicillin (MBC 0.2 mcg/mL or more); less-susceptible viridans streptococci or enterococci
                </td>
                <td>
                    Penicillin G or Ampicillin + Gentamicin (for first 2 weeks, or entire course for enterococci)
                </td>
                <td>
                    Vancomycin + Gentamicin for enterococci or Ampicillin + CefTRIAXone (for aminoglycoside (AMG)-resistant enterococci or AMG-intolerant patient) or CefTRIAXone + Gentamicin (not for enterococcal endocarditis)
                </td>
            </tr>
            <tr>
                <td>Resistant to penicillin</td>
                <td>Consult an infectious disease specialist.</td>
                <td>---</td>
            </tr>
            <tr>
                <td>
                    Staphylococci (S aureus or coagulase-negative staphylococci) †
                </td>
                <td></td>
                <td></td>
            </tr>
            <tr>
                <td>
                    Penicillin G susceptible (1 mcg/mL or less) (rare)
                </td>
                <td>Penicillin G</td>
                <td>Oxacillin or Nafcillin or First-generation cephalosporin or Vancomycin</td>
            </tr>
            <tr>
                <td>
                    Penicillin G resistant (0.1 mcg/mL)
                </td>
                <td>Oxacillin or Nafcillin with or without Gentamicin</td>
                <td>
                    Vancomycin (for those highly allergic to beta-lactam antibiotics) or First-generation cephalosporin
                </td>
            </tr>
            <tr>
                <td>Oxacillin (MRSA) resistant (4 mcg/mL)</td>
                <td>Vancomycin</td>
                <td>Daptomycin for right-sided endocarditis, maybe for left-sided</td>
            </tr>
            <tr>
                <td>Vancomycin resistant or intolerant</td>
                <td>Daptomycin</td>
                <td>Unknown</td>
            </tr>
            <tr>
                <td></td>
                <td colspan="2">†When prosthetic material present add riFAMpin + gentamicin (for first 2 weeks) for all staphylococci</td>
            </tr>
            <tr>
                <td style="text-align: left;">
                    Gram-negative enteric bacilli
                </td>
                <td>
                    CefTAZidime or Cefepime or Cefotaxime or CefTRIAXone <br>
                    Plus gentamicin (or tobramycin or amikacin, depending on susceptibility)
                </td>
                <td>
                    Broad-spectrum penicillin Plus gentamicin (or tobramycin or amikacin)
                </td>
            </tr>
            <tr>
                <td style="text-align: left;">HACEK group</td>
                <td>CefTRIAXone or Cefotaxime or Ampicillin-sulbactam</td>
                <td>Ampicillin (when susceptible) Plus aminoglycoside</td>
            </tr>
            <tr>
                <td colspan="3" style="text-align: left;">KEY: AMG = aminoglycosides; HACEK = Haemophilus species, Aggregatibacter species,Cardiobacterium hominis, Eikenella corrodens, and Kingella species; MBC = minimum bactericidal concentration, MRSA = methicillin-resistant Staphylococcus aureus (includes resistance to oxacillin, nafcillin, and cephalosporins)</td>
            </tr>
                <tr>
                  <td colspan="3" style="text-align: left;">Baltimore, 2015</td>
                </tr>
    </table>

        <p><strong>Meningitis:</strong> Empiric agents for the treatment of meningitis in neonates are ampicillin,gentamicin, and cefotaxime. Reassess therapy based on culture and sensitivity results</p>
        <p><strong>Sepsis</strong> caused by susceptible gram-negative organisms (e.g. E coil, H influenzae ,and Klebsiella). Optimal treatment for suspected, early-onset sepsis is broad-spectrum antimicrobial coverage using a combination of ampicillin and an aminoglycoside (usually gentamicin); once a pathogen is identified, therapy should be narrowed unless synergism is required.</p>
        
        <p><strong>Duration:</strong></p>
         <p>•Procalcitonin values in addition to perinatal risk factors, signs and symptoms, and laboratory values may aid in the determination to discontinue antibiotic therapy in neonates with suspected early-onset sepsis. The duration of antibiotic therapy was reduced by 9.9 hours with a procalcitonin-guided algorithm compared with standard care in a multicenter randomized control trial of 1710 neonates born after 34 weeks of gestational age with possible or unlikely sepsis. Re-infection and mortality was not different between the groups (risk difference 0.1% (95% CI,-5.2% to 5.3%)).</p>

        <p><strong>Pediatric FDA Approved Indications</strong></p>
        <p>Lower respiratory tract infections (including pneumonia) caused by streptococcus pneumonia,S pyogenes and other streptococci (excluding enterococci),(penicillinase and non-penicillinase producing),Escherichia coil,Kingella species, Haemophilus.influenzae(including ampicillin resistant strains),H parainfluenzae, Proteus mirabilis, Serratia marcescens, Enterobacter species, indole positive Proteus and Pseudomonas species (including P aeruginosa).</p>

        <p>Genitourinary infections (urinary tract infections) caused by Enterococcus species, S epidermidis, S aureus (penicillinase and non-penicillinase producing),Citrobacter species, Enterobacter species, E coil, Klebsiella species, P mirabilis, P vulgaris, P stuartii, M. morganii, P rettgerr, S marcescens, and Pseudomonas species (including P. aeruginosa). Also uncomplicated gonorrhea (cervical/urethral and rectal) caused by N. gonorrhoeae, including penicillinase-producing strains.</p>

        <p>Bacteremia/sepsis caused by E coil, Klebsiella species, and S marcescens, S aureus, and streptococcus species (including S pneumoniae).</p>

        <p>Skin and skin structure infections caused by S aureus (penicillinase and non-penicillinase producing), S epidermidis, S pyogenes and other streptococci, Enterococcus species, Acinetobacter species, E coil, Citrobacter species (including C freundii), Enterobacter species, Klebsiella species, P. mirabilis, P vulgaris, M. morganii, P rettgerr, Pseudomonas species, S marcescens, Bacteroides species, and anaerobic cocci (including Peptostreptococus species and Peptococcus species).</p>

        <p>Intra-abdominal infections caused by streptococcus species, E coil, Klebsiella species, Bacteroides species, anaerobic cocci (including Peptostreptococus species and Peptococcus species), P mirabilis, and Clostridium species. Cefotaxime plus metronidazole is considered an appropriate combination antibiotic regimen for pediatric patients with a complicated extra-biliary intra-abdominal infection.</p> 
          
        <p>Bone and/or joint infections caused by S aureus(penicillinase and non-penicillinase producing), streptococcus species (including S pyogenes), Pseudomonas species (including P aeruginosa), and P mirabilis.</p>

        <p> Central nervous system infections (eg, meningitis and ventriculitis) caused by N meningitidis, H influenzae, S pneumoniae, K pneumoniae, and E coil</p>

        <div class="section-title">Administration</div>
        <p>May be given by IM injection, IV push (over 3 to 5 minutes), or intermittent IV infusion. For IV push, a concentration of 50 to 100 mg/mL may be used. For intermittent IV infusion, dilute to a concentration of 10 to 40 mg/mL and infuse over 10 to 30 minutes.</p>

    <div class="section-header">MEDICATION SAFETY</div>
  
      <div class="section-title">Contraindications/ Precautions</div>
        <p><strong>Extravasation, including extensive perivascular,</strong> may occur causing tissue damage requiring surgical intervention</p>
        <p>Use cautiously in patients with a <strong>history of gastrointestinal disease,</strong> especially colitis</p>
        <p><strong>Clostridium difficile-associated diarrhea,</strong> ranging from mild diarrhea to fatal colitis, has been reported. Discontinuation may be required</p>
        <p><strong>Leukopenia, neutropenia, or granulocytopenia</strong> and in rare cases <strong>bone marrow failure, pancytopenia, or agranulocytosis </strong>may occur</p>
        <p>Increased risk of <strong>allergic reaction</strong> including serious reactions requiring medical intervention in patients with previous hypersensitivity to penicillins, other drugs, or other demonstrated allergy</p>
        <p><strong>Drug-resistant bacteria</strong> may develop if used in the absence of bacterial infection</p>
        <p>Use caution in the presence of <strong>renal insufficiency.</strong> Dose reductions are recommended with CrCL less than 20 mL/min/1.73 m(2)</p>
        <p><strong>Rapid bolus injection via a central venous catheter</strong> has resulted in life-threatening arrhythmias</p>
        <p>A <strong>false-positive</strong> reaction for urine glucose may occur with copper reduction test. Enzyme-based tests for glycosuria are recommended</p>

      <div class="section-title">Adverse Effects</div>
        <p>Side effects are rare but include rash, phlebitis, diarrhea, leukopenia, granulocytopenia, and eosinophilia.</p>
        <p>In a prospective cohort study (n=4579), third generation cephalosporins started by day 3 of life in extremely low birth weight infants (less than 1000 g) were associated with a significantly increased risk of candidiasis compared with other antibiotics.</p>

<div class="section-title">Solution Compatibility</div>
        <p>D5W, D10W, and NS.</p>

<div class="section-title">Terminal Injection Site Compatibilit</div>
        <p>Acyclovir, alprostadil, amikacin, aztreonam, caffeine citrate, cimetidine, clindamycin, famotidine, gentamicin, heparin, lorazepam, magnesium sulfate, metronidazole, midazolam, milrinone, morphine, oxacillin, penicillin g, potassium chloride, propofol, and remifentanil.</p>

<div class="section-title">Terminal Injection Site Incompatibility</div>
        <p>Azithromycin, fluconazole, protamine sulfate, sodium bicarbonate, and vancomycin.</p>

<div class="section-title">Monitoring</div>
        <p>Measuring serum concentration is not usually necessary. Periodic CBC.</p>


    <div class="section-header">MECHANISM OF ACTION/PHARMACOKINETICS</div>
    
      <div class="section-title">Pharmacology</div>
      <p><strong>Mechanism of action:</strong> Cefotaxime is one of many third-generation cephalosporin antibiotics. The mechanism of action appears to be by bacterial cell wall disruption.</p>
      <p><strong>Pharmacokinetics</strong></p>
      <p>Metabolized in the liver to an active compound, desacetylcefotaxime. The drug distributes widely (i.e. CSF, bile, bronchial secretions, lung tissue, ascitic fluid, middle ear). Excreted renally as unchanged drug (20% to 36%) and active metabolite (15% to 25%).</p>
      <p><strong>Vd:</strong> 0.64 L/kg in 100 infants with a median postnatal age of 9 days (0 to 69 days), median gestational age of 31.5 weeks (23 to 42 weeks), postmenstrual age of 33 weeks (25 to 44 weeks), and birth weight of 1,415 g (512 g to 3,990 g).</p>
      <p><strong>CL:</strong> 0.12 L/kg/hr (0.04 to 0.26 L/kg/hr) in 100 infants with a median postnatal age of 9 days (0 to 69 days), median gestational age of 31.5 weeks (23 to 42 weeks), postmenstrual age of 33 weeks (25 to 44 weeks), and birth weight of 1,415 g (512 g to 3,990 g).</p>
      <p><strong>Half-life:</strong> 3.63 hours (1.67 to 10.35 hours) in 100 infants with a median postnatal age of 9 days (0 to 69 days), median gestational age of 31.5 weeks (23 to 42 weeks), postmenstrual age of 33 weeks (25 to 44 weeks), and birth weight of 1,415 g (512 g to 3,990 g)</p>

    <div class="section-header">ABOUT</div>
    
      <div class="section-title">Special Considerations/Preparation</div>
      <p><strong>Available</strong> as powder for injection in 500-mg, 1-g, and 2-g vials.</p>
      <p><strong>Reconstitution</strong></p>
      <p><strong>For IM use:</strong> Dilute the 500-mg, 1-g, and 2-g vials with 2, 3, and 5 mL of sterile water for injection or bacteriostatic water for injection, respectively, for concentrations of 230, 300,and 330 mg/mL, respectively.</p>
      <p><strong>For IV use:</strong> Dilute the 500-mg, 1-g, and 2-g vials with 10 mL of sterile water for injection to yield concentrations of 50, 95, and 180 mg/mL, respectively.</p>
      <p><strong>Storage:</strong> Reconstituted solution for IV use is stable for 24 hours at room temperature and 7 days refrigerated.</p>

        <div class="button-group">
            <a href="javascript:history.back()" class="back-button-secondary">Back</a>
            <a href="{{ url_for('index') }}" class="back-button">Back to Home</a>
        </div>
    
        <footer>
            <p>Developed by Sukhontha Boonsookchan | update {{ update_date }}</p>
        </footer>

</body>
</html>